June 16, 2023 Epicrispr Biotechnologies Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
May 23, 2023 Epicrispr Biotechnologies to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023
May 19, 2023 Epicrispr Biotechnologies Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
May 4, 2023 Epicrispr Biotechnologies to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
April 18, 2023 SOLVE FSHD Invests in Epicrispr Biotechnologies to Advance Potentially Curative Therapy
March 29, 2023 Epicrispr Biotechnologies to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
March 14, 2023 In Pivotal Demonstration, Epicrispr Biotechnologies Accomplishes Persistent Gene Activation with Single Administration
March 6, 2023 Epicrispr Biotechnologies Announces Presentations at Upcoming Scientific and Medical Conferences
December 7, 2022 Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies, Recognized by Endpoints News as One of the Most Influential Women in Biopharma R&D
October 31, 2022 Epicrispr Biotechnologies Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery
October 25, 2022 Epicrispr Biotechnologies to Participate in the 6th International Conference on Epigenetics and Bioengineering
